Postural orthostatic tachycardia syndrome (POTS) is a debilitating condition marked by a rapid increase in heart rate when standing up. While there are currently no effective treatments available, Ivabradine–a drug commonly used for heart failure and heart-related chest pain–has been shown in prior studies to be beneficial for POTS patients. 

This study tested the efficacy of Ivabradine in treating patients with POTS study and was the first of its kind. Current treatments for POTS have limited efficacy and are often accompanied by harsh side effects that limit their use. It was found ivabradine significantly improved heart rate and quality of life.

Cameron's favorite part about the study was seeing research's potential to foster hope and advocate for better, more effective treatments. Many patients with POTS from around the country have since reached out to explain how important it is for the POTS and dysautonomia community to see research is being done to improve their care.

Cameron has presented the study findings at several national and international research conferences. Cameron was also a co-author on the subsequent paper, which was published in the Journal of the American College of Cardiology.

Below are a few of slides from his presentation.